An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis

Biological Psychiatry

Volumn 81, Issue 6, 2017, Pages 470-477

  Vassos, Evangelos ^a   Di Forti, Marta ^a   Coleman, Jonathan ^a   Iyegbe, Conrad ^a   Prata, Diana ^a,b   Euesden, Jack ^a   O'Reilly, Paul ^a   Curtis, Charles ^a,c   Kolliakou, Anna ^a   Patel, Hamel ^a,c   Newhouse, Stephen ^a,c   Traylor, Matthew ^a   Ajnakina, Olesya ^a   Mondelli, Valeria ^a,b   Marques, Tiago Reis ^a   Gardner Sood, Poonam ^a   Aitchison, Katherine J ^a,d   Powell, John ^a   Atakan, Zerrin ^a   Greenwood, Kathryn E ^e   Smith, Shubulade ^a,c   Ismail, Khalida ^a   Pariante, Carmine ^a   Gaughran, Fiona ^a   Dazzan, Paola ^a,c   Markus, Hugh S ^f   David, Anthony S ^a   Lewis, Cathryn M ^a   Murray, Robin M ^a   Breen, Gerome ^a,c   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Genetics; GWAS; Polygenic score; Psychosis; Risk prediction; Schizophrenia

Indexed keywords

ADULT; AFRICAN; ANCESTRY GROUP; ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; EUROPEAN; FEMALE; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); POLYGENIC RISK SCORE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; BLACK PERSON; CASE CONTROL STUDY; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; MULTIFACTORIAL INHERITANCE; PSYCHOTIC DISORDERS; RISK FACTOR; YOUNG ADULT;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MULTIFACTORIAL INHERITANCE; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85005846735     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.06.028     Document Type: Article

References (46)

1. 1 Gibson, G., Rare and common variants: Twenty arguments. Nat Rev Genet 13 (2012), 135–145.
2. 2 Psychiatric Genomics Consortium Schizophrenia Working Group. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (2014), 421–427.
3. 3 So, H.C., Kwan, J.S., Cherny, S.S., Sham, P.C., Risk prediction of complex diseases from family history and known susceptibility loci, with applications for cancer screening. Am J Hum Genet 88 (2011), 548–565.
4. 4 Maier, R., Moser, G., Chen, G.B., Ripke, S., Cross-Disorder Working Group of the Psychiatric Genomics Consortium, Coryell, W., et al. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. Am J Hum Genet 96 (2015), 283–294.
5. 5 International Schizophrenia Consortium, Purcell, S.M., Wray, N.R., Stone, J.L., Visscher, P.M., O'Donovan, M.C., Sullivan, P.F., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460 (2009), 748–752.
6. 6 Chatterjee, N., Wheeler, B., Sampson, J., Hartge, P., Chanock, S.J., Park, J.H., Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies. Nat Genet 45 (2013), 400–405 405e1–3.
7. 7 Dudbridge, F., Power and predictive accuracy of polygenic risk scores. PLoS Genet, 9, 2013, e1003348.
8. 8 Janssens, A.C., Ioannidis, J.P., Bedrosian, S., Boffetta, P., Dolan, S.M., Dowling, N., et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): Explanation and elaboration. Eur J Hum Genet, 19, 2011, 18 p preceding 494.
9. 9 Di Forti, M., Iyegbe, C., Sallis, H., Kolliakou, A., Falcone, M.A., Paparelli, A., et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72 (2012), 811–816.
10. 10 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. 1992, WHO, Geneva.
11. 11 World Health Organization, Division of Mental Health (1999): Schedules for Clinical Assessment in Neuropsychiatry (Version 2.1), 2.1. ed. Geneva: WHO Assessment, Classification and Epidemiology.
12. 12 Bebbington, P., Nayani, T., The Psychosis Screening Questionnaire. Int J Method Psych 5 (1995), 11–19.
13. 13 Sheitman, B.B., Lee, H., Strous, R., Lieberman, J.A., The evaluation and treatment of first-episode psychosis. Schizophr Bull 23 (1997), 653–661.
14. 14 McGuffin, P., Farmer, A., Harvey, I., A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48 (1991), 764–770.
15. 15 Gaughran, F., Stahl, D., Ismail, K., Atakan, Z., Lally, J., Gardner-Sood, P., et al. Improving physical health and reducing substance use in psychosis—Randomised control trial (IMPACT RCT): Study protocol for a cluster randomised controlled trial. BMC Psychiatry, 13, 2013, 263.
16. 16 Gardner-Sood, P., Lally, J., Smith, S., Atakan, Z., Ismail, K., Greenwood, K.E., et al. Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: Baseline data from the IMPaCT randomized controlled trial. Psychol Med 45 (2015), 2619–2629.
17. 17 Khan, U., Crossley, C., Kalra, L., Rudd, A., Wolfe, C.D., Collinson, P., et al. Homocysteine and its relationship to stroke subtypes in a UK black population: The south London ethnicity and stroke study. Stroke 39 (2008), 2943–2949.
18. 18 Howie, B.N., Donnelly, P., Marchini, J., A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. Plos Genet, 5, 2009, e1000529.
19. 19 1000 Genomes Project Corsortium, Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491 (2012), 56–65.
20. 20 Howie, B., Marchini, J., Stephens, M., Genotype imputation with thousands of genomes. G3 (Bethesda) 1 (2011), 457–470.
21. 21 Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., Lee, J.J., Second-generation PLINK: Rising to the challenge of larger and richer datasets. Gigascience, 4, 2015, 7.
22. 22 Psychosis Endophenotypes International Consortium, Wellcome Trust Case-Control Consortium 2, Bramon, E., Pirinen, M., Strange, A., Lin, K., et al. A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol Psychiatry 75 (2014), 386–397.
23. 23 Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., Reich, D., Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38 (2006), 904–909.
24. 24 Euesden, J., Lewis, C.M., O'Reilly, P.F., PRSice: Polygenic Risk Score software. Bioinformatics 31 (2015), 1466–1468.
25. 25 Saha, S., Chant, D., Welham, J., McGrath, J., A systematic review of the prevalence of schizophrenia. PLoS Med, 2, 2005, e141.
26. 26 Agerbo, E., Sullivan, P.F., Vilhjalmsson, B.J., Pedersen, C.B., Mors, O., Borglum, A.D., et al. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: A Danish population-based study and meta-analysis. JAMA Psychiatry 72 (2015), 635–641.
27. 27 Morgan, C., Dazzan, P., Morgan, K., Jones, P., Harrison, G., Leff, J., et al. First episode psychosis and ethnicity: Initial findings from the AESOP study. World Psychiatry 5 (2006), 40–46.
28. 28 Mowry, B.J., Gratten, J., The emerging spectrum of allelic variation in schizophrenia: Current evidence and strategies for the identification and functional characterization of common and rare variants. Mol Psychiatry 18 (2013), 38–52.
29. 29 Gottesman, I.I., Shields, J., A polygenic theory of schizophrenia. Proc Natl Acad Sci U S A 58 (1967), 199–205.
30. 30 Janssens, A.C., Aulchenko, Y.S., Elefante, S., Borsboom, G.J., Steyerberg, E.W., van Duijn, C.M., Predictive testing for complex diseases using multiple genes: Fact or fiction?. Genet Med 8 (2006), 395–400.
31. 31 Trotta, A., Di Forti, M., Mondelli, V., Dazzan, P., Pariante, C., David, A., et al. Prevalence of bullying victimisation amongst first-episode psychosis patients and unaffected controls. Schizophr Res 150 (2013), 169–175.
32. 32 Crews, M., Lally, J., Gardner-Sood, P., Howes, O., Bonaccorso, S., Smith, S., et al. Vitamin D deficiency in first episode psychosis: A case-control study. Schizophr Res 150 (2013), 533–537.
33. 33 Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. Lancet Psychiat 2 (2015), 233–238.
34. 34 Stilo, S.A., Di Forti, M., Mondelli, V., Falcone, A.M., Russo, M., O'Connor, J., et al. Social disadvantage: Cause or consequence of impending psychosis?. Schizophrenia Bull 39 (2013), 1288–1295.
35. 35 Tesli, M., Espeseth, T., Bettella, F., Mattingsdal, M., Aas, M., Melle, I., et al. Polygenic risk score and the psychosis continuum model. Acta Psychiatr Scand 130 (2014), 311–317.
36. 36 Bigdeli, T.B., Bacanu, S.A., Webb, B.T., Walsh, D., O'Neill, F.A., Fanous, A.H., et al. Molecular validation of the schizophrenia spectrum. Schizophr Bull 40 (2014), 60–65.
37. 37 Tishkoff, S.A., Reed, F.A., Friedlaender, F.R., Ehret, C., Ranciaro, A., Froment, A., et al. The genetic structure and history of Africans and African Americans. Science 324 (2009), 1035–1044.
38. 38 Balding, D.J., A tutorial on statistical methods for population association studies. Nat Rev Genet 7 (2006), 781–791.
39. 39 Kendler, K.S., Karkowski-Shuman, L., O'Neill, F.A., Straub, R.E., MacLean, C.J., Walsh, D., Resemblance of psychotic symptoms and syndromes in affected sibling pairs from the Irish Study of High-Density Schizophrenia Families: Evidence for possible etiologic heterogeneity. Am J Psychiatry 154 (1997), 191–198.
40. 40 Tandon, R., Keshavan, M.S., Nasrallah, H.A., Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102 (2008), 1–18.
41. 41 Ioannidis, J.P., Ntzani, E.E., Trikalinos, T.A., ‘Racial’ differences in genetic effects for complex diseases. Nat Genet 36 (2004), 1312–1318.
42. 42 de Candia, T.R., Lee, S.H., Yang, J., Browning, B.L., Gejman, P.V., Levinson, D.F., et al. Additive genetic variation in schizophrenia risk is shared by populations of African and European descent. Am J Hum Genet 93 (2013), 463–470.
43. 43 Cooper, B., Immigration and schizophrenia: The social causation hypothesis revisited. Br J Psychiatry 186 (2005), 361–363.
44. 44 Fearon, P., Kirkbride, J.B., Morgan, C., Dazzan, P., Morgan, K., Lloyd, T., et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: Results from the MRC AESOP Study. Psychol Med 36 (2006), 1541–1550.
45. 45 Trierweiler, S.J., Neighbors, H.W., Munday, C., Thompson, E.E., Binion, V.J., Gomez, J.P., Clinician attributions associated with the diagnosis of schizophrenia in African American and non-African American patients. J Consult Clin Psychol 68 (2000), 171–175.
46. 46 Medina-Gomez, C., Felix, J.F., Estrada, K., Peters, M.J., Herrera, L., Kruithof, C.J., et al. Challenges in conducting genome-wide association studies in highly admixed multi-ethnic populations: The Generation R Study. Eur J Epidemiol 30 (2015), 317–330.